-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on GoodRx Holdings, Lowers Price Target to $5.25

Benzinga·05/13/2025 15:52:13
Listen to the news
UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and lowers the price target from $6 to $5.25.